Investing.com - InMed Pharmaceuticals reported on Friday third quarter earnings that beat analysts' forecasts and revenue that fell short of expectations.
InMed Pharmaceuticals announced earnings per share of $-4.060 on revenue of $320.79K. Analysts polled by Investing.com anticipated EPS of $-4.250 on revenue of $500K.
InMed Pharmaceuticals shares are down 90% from the beginning of the year, still down 94.94% from its 52 week high of $59.25 set on November 17, 2021.
InMed Pharmaceuticals follows other major Healthcare sector earnings this month
InMed Pharmaceuticals's report follows an earnings beat by UnitedHealth on October 14, who reported EPS of $5.79 on revenue of $80.89B, compared to forecasts EPS of $5.43 on revenue of $80.52B.
J&J had beat expectations on October 18 with third quarter EPS of $2.55 on revenue of $23.79B, compared to forecast for EPS of $2.52 on revenue of $23.46B.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar